设为首页收藏本站

中国病毒学论坛|我们一直在坚持!

 找回密码
 立即注册

QQ登录

只需一步,快速开始

搜索
热搜: 活动 交友 discuz
查看: 2232|回复: 5
打印 上一主题 下一主题

疫苗学《Vaccines》——6th Edition by (美)普洛特金

[复制链接]

1067

帖子

1032

学分

1万

金币

管理员

Rank: 9Rank: 9Rank: 9Rank: 9

积分
1032
QQ
跳转到指定楼层
楼主
发表于 2015-7-25 14:07:34 | 只看该作者 回帖奖励 |倒序浏览 |阅读模式

& N# n) {. F% o6 q+ |4 A* f+ x( y2 Q& j
Vaccines, 6th Edition
! F9 _: @$ N: E; I) T6 B$ n
Apply the latest vaccination knowledge with a reference that Bill Gates calls "an indispensable guide to the enhancement of the well-being of our world." Inside Vaccines, you’ll find comprehensive and current coverage of every aspect of vaccination, from the development of each vaccine to its use in reducing disease. This medical reference book offers the expert information you need to apply the very latest techniques and information in your practice.
# V, v  d: m  M: {  L& w; C4 }/ w
* ^7 H- R6 w* X% m9 Y, ~( g
http://yun.baidu.com/share/link?shareid=2079860221&uk=3810996606, ?! U& }1 S- w% G+ `
. p- F5 _  L0 k7 o, ~3 Q
SECTION 1: General aspects of vaccination
: i2 e0 X4 p  l# k# x5 w1 A short history of vaccination 1
% ^' d: H& U  o3 ]+ n# d( x. |% n2 Vaccine immunology 14
! y8 T4 u& `/ Z+ o6 I. C3 The vaccine industry 337 ?3 z, ?3 D4 z$ {6 ^' n" E9 ^3 W0 W
4 Vaccine manufacturing 440 K$ r6 f, d; H5 V% T% H
5 Evolution of adjuvants across the centuries 58/ N- \& m2 B2 p7 B
6 Vaccine additives and manufacturing residuals in the United States:) H- \  U1 P& Q$ h* r' k
licensed vaccines 71
7 K3 K; v2 E) V% b9 c) ?7 Passive immunization 80
( m: @; N8 G* }0 @! I8 General immunization practices 88  }  ^7 ?9 m# t
SECTION 2: Licensed vaccines
' q1 |- A1 `- l* d/ [* _9 Adenovirus vaccines 113
4 R: t' P9 F2 P" [% b, H  u10 Anthrax vaccines 127
' ?, P$ q: k$ G1 K11 Cholera vaccines 141: d4 @7 B/ G+ F! R/ B
12 Diphtheria toxoid 1530 d6 y2 G6 k- g2 v4 z8 I
13 Haemophilus influenzae vaccines 167
; \% e/ g9 r8 _1 @14 Hepatitis A vaccines 183
/ |8 p9 t+ |( V$ `: d7 G15 Hepatitis B vaccines 205' t7 Q" h, Y' m( @! ~
16 Human papillomavirus vaccines 235
2 y2 y# r! D2 Q% g$ J: ^17 Inactivated influenza vaccines 257
0 z# t4 k+ C: J6 X; e( B18 Influenza vaccine-live 2943 ?8 ^4 Y5 F# z! v
19 Japanese encephalitis vaccines 312! H( n3 V" ~, V4 k' v: @
20 Measles vaccines 352) X, ?( e3 [7 a0 X/ r8 Q
21 Meningococcal vaccines 388
$ C6 @$ \% h" n22 Mumps vaccine 419! i! U' q1 s; k! n
23 Pertussis vaccines . 447
6 H/ N& }. C! t7 x2 ^( ?% f' Z( E24 Plague vaccines 4934 S" p8 h! Z4 n7 Z$ V  l; q! j) ^
25 Pneumococcal conjugate vaccine and pneumococcal common protein vaccines 5042 H; f0 n4 o( |
26 Pneumococcal polysaccharide vaccines 5428 d! _4 z. m3 \6 `- w  }
27 Poliovirus vaccine-inactivated . 573
5 w& i( _$ J: ^6 v* U+ Y. s+ O28 Poliovirus vaccine-live 598
9 v$ X# }7 V% q29 Rabies vaccines .646
& Z* l2 X0 _$ w" ~30 Rotavirus vaccines . 669& r( n- ^' c% l' o  q
31 Rubella vaccine 6883 v0 M! B  u& u0 L2 V+ i+ c
32 Smallpox and vaccinia 718
- _2 n) t) E2 q% m7 k4 }1 X" u33 Tetanus toxoid 746
' I9 Z5 E8 ~; r9 \: X; j# L$ h34 Tick-borne encephalitis virus vaccines 773
7 B, ]+ f/ q; o6 A35 Tuberculosis vaccines 789
3 l$ \5 b( H& I+ x& M0 V3 \+ f36 Typhoid fever vaccines 812
/ C# y" v! h' K5 r. M: f37 Varicella vaccine 837' y7 K' e! x# L; F
38 Yellow fever vaccine 8700 W6 y. V+ b: q. R1 `1 M
39 Zoster vaccine 969
) C3 Y# h; S9 l* F/ m40 Combination vaccines 981! Y" X8 m# k0 j: h' Q+ `
SECTION 3: Vaccines in development and new vaccine strategies; b+ n9 L  k; t) i/ u
41 Biodefense and special pathogen vaccines 1008
) I5 X$ y* R5 {8 j) L42 Therapeutic cancer vaccines 1018' [: w) s0 S6 T  L
43 Cytomegalovirus vaccines 1032
  b8 Q) B! N, n( F) B44 Dengue vaccines 1042
/ b8 v/ T& ^9 ~45 Diarrhea caused by bacteria 1052
4 L0 V, j4 t, E2 |) r46 Ebola vaccine 1060
& [' E9 c! D6 U/ |5 p  C47 Epstein-Barr virus vaccines 1068
! Q  l) h" R6 V2 A4 e48 Hepatitis C vaccines 1074
, \' C; |, W2 Y, m8 W49 Hepatitis E vaccines 1085
; X9 N2 q; N! W' Z) p. u1 x. T50 Herpes simplex virus vaccines 1090
& S. N/ L9 l8 c: p  p51 Human immunodeficiency virus vaccines 10978 B% S& p3 P2 M5 S: C
52 Lyme disease vaccines 1122
& B* V" }" N8 V53 Malaria vaccines 1133
9 v; Z* O& Q  q+ T9 T3 W54 Noninfectious disease vaccines 1138
4 L# W7 I% P& p4 ?7 _55 Respiratory syncytial virus and parainfluenza virus vaccines 11469 Z0 |9 t$ |+ B: e: d
56 Parasitic disease vaccines 1154
& O$ T2 A; n4 h$ |" B( [' g/ y57 Staphylococcus aureus vaccines 1161
) {; @: b( J6 L4 s58 Streptococcus group A vaccines 11695 r, K/ Z  i6 P+ g! C8 n0 f9 K
59 Streptococcus group B vaccines 1176
' _- q6 R* z! z4 m- B% O+ ?60 Technologies for making new vaccines 11828 l8 ]+ }6 e( n/ L% E
61 Alternative vaccine delivery methods 1200
" L, {" i7 j$ `62 The development of gene-based vectors for immunization 1232% v  K! l) K  j; E: n) d" z
SECTION 4: Vaccination of special groups' f( T" h$ d- o( k1 l' Z
63 Vaccination of immunocompromised hosts 1243
& P) e8 @/ z' R  w% X0 z  O64 Vaccination of human immunodeficiency virus-infected persons 1257+ U4 c  ~1 e% O; Q& H* W9 p
65 Vaccines for international travel 1270
( b9 V+ a! a3 z2 i66 Vaccines for health care personnel 1290
2 y! _. g8 @; L3 pSECTION 5: Public health and regulatory issues
8 M: s/ p8 w' p0 V: P0 T. G  O4 c/ {67 Immunization in the United States 1310
4 n* z  Y$ f# ^  i: q' h9 H4 ^68 Immunization in Europe . 1334
+ ?6 x" F) i) P9 Y( Y69 Immunization in the Asia-Pacific region 1353
8 V$ O: O* v2 @: G, B70 Immunization in developing countries 1369) A& G7 Z& N* Y) A3 o( ]
71 Community immunity 1395
  u1 h# m( D4 p( m8 g" v4 u72 Economic analyses of vaccine policies 14139 F( L$ H. G) r' J! ~) L. `
73 Regulation and testing of vaccines 1427
6 ~5 g) G% L- @8 q; {74 Regulation of vaccines in Europe 1447  w( B6 V2 L, |' W
75 Regulation of vaccines in developing countries 1454/ H# U0 _% h2 ?( M$ [- W
76 Vaccine safety 1464
5 x% ]* G% m& z7 k! s9 n  d77 Legal issues . 1481
, n. V3 J! L' `1 U; F/ F78 Ethics 1508
' [$ M- v) |, G3 l) N3 @- j  m6 o
. I! ]- O" `4 C
: z& {5 H/ u' t$ a2 l& m/ t5 e1 v# x; ?) ?. g+ n  d! S1 M3 U

( [) p" ]& j, L; q" G# ?0 g0 N; ^0 K
分享到:  QQ好友和群QQ好友和群 QQ空间QQ空间 腾讯微博腾讯微博 腾讯朋友腾讯朋友
收藏收藏 分享分享 支持支持 反对反对

7

帖子

2

学分

357

金币

病毒学院小学生

Rank: 2Rank: 2

积分
2
沙发
发表于 2015-7-26 14:55:58 | 只看该作者
非常感谢

36

帖子

27

学分

3544

金币

病毒学院中学生

Rank: 3Rank: 3Rank: 3

积分
27
板凳
发表于 2015-8-13 17:54:21 | 只看该作者
谢谢分享

36

帖子

27

学分

3544

金币

病毒学院中学生

Rank: 3Rank: 3Rank: 3

积分
27
地板
发表于 2015-8-13 17:55:46 | 只看该作者
怎么看不到相关下载呀

1067

帖子

1032

学分

1万

金币

管理员

Rank: 9Rank: 9Rank: 9Rank: 9

积分
1032
QQ
5#
 楼主| 发表于 2015-8-13 21:26:48 | 只看该作者

6 R% T$ R6 \5 K9 F0 @+ o+ v& S% JVaccines, 6th Edition8 J# d! R* K9 w( U

4 S* U' |/ P* E; H' N- AApply the latest vaccination knowledge with a reference that Bill Gates calls "an indispensable guide to the enhancement of the well-being of our world." Inside Vaccines, you’ll find comprehensive and current coverage of every aspect of vaccination, from the development of each vaccine to its use in reducing disease. This medical reference book offers the expert information you need to apply the very latest techniques and information in your practice.0 z8 t4 u9 d" z8 c/ S" I3 B/ Q
! I4 h4 Q8 b3 @( u% H
http://yun.baidu.com/share/link? ... 1&uk=3810996606: H( Y/ _/ d/ q/ u" M" n5 w

  w6 i7 @, C2 m: USECTION 1: General aspects of vaccination$ N5 j) ~& k& C' g* s* M. T
1 A short history of vaccination 1
3 I/ C% H/ r4 p1 i: M! E1 X0 l3 e. T2 Vaccine immunology 14
* e% }& g5 N/ h; B3 The vaccine industry 33
, g' O1 e( v' W% w4 M1 V4 Vaccine manufacturing 44+ f) P9 J* V7 [
5 Evolution of adjuvants across the centuries 582 r. E9 {: x; h+ U' |: F8 C
6 Vaccine additives and manufacturing residuals in the United States:3 p* _! W9 @) t4 o0 b
licensed vaccines 71
4 O0 m( H; L7 k/ x5 o1 e1 `. |8 `* L7 Passive immunization 80: a+ w. [+ b$ F) \8 ^
8 General immunization practices 88; D) e$ |( }: ]9 @6 y9 r3 A* c% C; V
SECTION 2: Licensed vaccines
, X' K) D* o+ ~! {9 Adenovirus vaccines 1136 }+ t, [% s/ l# y
10 Anthrax vaccines 127
* }$ ~4 Q  `% Y% J) ~) w11 Cholera vaccines 141
& \7 s0 Q7 `+ n& z+ s12 Diphtheria toxoid 153
1 {2 r5 B1 D% [& u, f7 U! i$ q0 {13 Haemophilus influenzae vaccines 167. D2 j. _+ K' A& R7 e- Y
14 Hepatitis A vaccines 1831 k/ V6 M4 v* I. I. K# G. k$ e4 P
15 Hepatitis B vaccines 205
2 L( y$ J! ]' j7 R7 ?; w+ l* n/ F: `16 Human papillomavirus vaccines 235
7 u0 [$ E. g3 q5 j2 m17 Inactivated influenza vaccines 257
7 U: x3 q7 ~+ j% d18 Influenza vaccine-live 2949 ~/ @! X5 B1 ~, r
19 Japanese encephalitis vaccines 312
' `- O2 I+ `" R20 Measles vaccines 352
1 @& k- N+ F( ~$ ], E# R. K21 Meningococcal vaccines 3884 r4 d, n, N2 f. ~+ i5 n! w, ~' _
22 Mumps vaccine 419
+ k( c- U7 _7 N9 b. s- I2 r23 Pertussis vaccines . 447. y+ o3 w5 X- o  c2 t4 Y0 I( W. [
24 Plague vaccines 493' o* Y4 Q; Y7 [$ \& `6 y
25 Pneumococcal conjugate vaccine and pneumococcal common protein vaccines 504
4 L( e+ M0 l% r& ?: K5 t& y5 C" }0 o26 Pneumococcal polysaccharide vaccines 542* C, U7 C, ^3 h  ^! J+ V5 S# _
27 Poliovirus vaccine-inactivated . 573$ p7 V1 {# u% i: n: I
28 Poliovirus vaccine-live 5984 K( @$ m: M9 }) d! ?- b4 |
29 Rabies vaccines .646
7 n2 \& d* a  {9 B9 ]  D30 Rotavirus vaccines . 669
' f3 @7 _1 {7 B/ L7 _" _% t) [* J8 {31 Rubella vaccine 688
1 d* D# A/ o4 q0 V9 t32 Smallpox and vaccinia 718% K" f  ~3 }4 V1 S/ m
33 Tetanus toxoid 746
7 N7 g8 G# W# X. j' m34 Tick-borne encephalitis virus vaccines 773
8 M- m% B. l# a& A35 Tuberculosis vaccines 789
1 z6 V: o- t9 C6 J4 G, x36 Typhoid fever vaccines 812- b% K! J, u8 c$ H
37 Varicella vaccine 837
9 d; I) d, s- R/ m38 Yellow fever vaccine 870
- J: c( q* e/ s0 [# W39 Zoster vaccine 969' Q$ \1 z2 g3 X: M' u2 U
40 Combination vaccines 981# L+ C0 ?6 d! I) S' M
SECTION 3: Vaccines in development and new vaccine strategies
( K" E0 \2 t5 m( ~; P41 Biodefense and special pathogen vaccines 1008$ q7 U7 X# P3 P4 D) C1 M
42 Therapeutic cancer vaccines 1018
/ e, |& v# N+ F' T0 n" Z43 Cytomegalovirus vaccines 1032* H, V2 s2 @5 ^- z4 x3 u
44 Dengue vaccines 1042, `# N" G# a! G/ J# p5 A
45 Diarrhea caused by bacteria 1052, q: Q  s, G4 D  _
46 Ebola vaccine 1060: ^' Q3 p2 s0 I$ E: A1 ]
47 Epstein-Barr virus vaccines 10689 b+ |- F) a1 ]) m% R
48 Hepatitis C vaccines 1074
5 O" z( H) F9 R. T49 Hepatitis E vaccines 1085) O  g. M0 g, f7 \3 L# d: L
50 Herpes simplex virus vaccines 1090( Q1 Q$ k/ _7 l/ e
51 Human immunodeficiency virus vaccines 1097
" M( B  m: d' Q: r3 V52 Lyme disease vaccines 11221 n8 \1 X( l0 f- P5 g$ [
53 Malaria vaccines 1133  M3 x5 r$ x* x) b- O  s& Q9 |
54 Noninfectious disease vaccines 1138
5 t6 L: B6 \; X' r55 Respiratory syncytial virus and parainfluenza virus vaccines 11468 ^2 @9 |8 c7 [* a/ l3 I- g5 D
56 Parasitic disease vaccines 1154
" H4 X) |! p) I; @/ ^, G! U/ {2 |57 Staphylococcus aureus vaccines 1161
9 j2 B% B4 m* }58 Streptococcus group A vaccines 1169
" o+ Y9 D% P6 O; F! S# b) @59 Streptococcus group B vaccines 1176
5 ?& _$ X8 ^& Z60 Technologies for making new vaccines 1182
' K0 U( T" Z/ a2 {4 M  c61 Alternative vaccine delivery methods 1200
  |& p9 j+ F4 X62 The development of gene-based vectors for immunization 1232
8 V( l% Q9 c: O- f  M6 d3 FSECTION 4: Vaccination of special groups3 H) r9 M. u  l) W, C8 y
63 Vaccination of immunocompromised hosts 1243# |, o% E. g  C. @' f5 k3 F
64 Vaccination of human immunodeficiency virus-infected persons 1257$ y) U& |4 ~% |1 u( {+ m. Y
65 Vaccines for international travel 1270
4 d% c- R8 f' O' D1 Y6 j  a66 Vaccines for health care personnel 1290( G7 v6 j& p/ ?4 o- T: c
SECTION 5: Public health and regulatory issues7 H2 c* h9 O# _. e1 V" L9 ?" i  L
67 Immunization in the United States 13108 V! i2 @& Y" U/ K6 o
68 Immunization in Europe . 1334
# d) P- |( \# C5 P1 B- X69 Immunization in the Asia-Pacific region 13537 |: W/ ^  J" g  F1 h7 W
70 Immunization in developing countries 1369
! z4 d1 R7 a( k* J71 Community immunity 13956 u& ~" U2 C% H* j; N$ q0 g1 o( l
72 Economic analyses of vaccine policies 1413" T5 c+ _9 g7 s/ }- z
73 Regulation and testing of vaccines 1427
  k9 D; w/ |9 S8 }! x' v74 Regulation of vaccines in Europe 1447
( v: w) ~; I9 r# A7 i75 Regulation of vaccines in developing countries 14547 h& P% W; C0 g: [# H
76 Vaccine safety 1464, I# Y+ E+ g. o( q$ S0 b
77 Legal issues . 1481
% c  U/ O' u  }6 R3 J- I; e78 Ethics 1508: i6 L( |+ e& h' E6 E% G

  W+ o4 a* s& a  K4 ]: y( s  n& }. L( f9 ?+ Z8 q* s. |

23

帖子

39

学分

5741

金币

病毒学院中学生

Rank: 3Rank: 3Rank: 3

积分
39
6#
发表于 2017-5-2 15:25:27 | 只看该作者
Vaccines, 6e, 2012
& ?# q; Z+ V% X- }5 C/ U) R" V' w1 q) \. d* r
Hardcover: 1570 pages0 K9 A. W) w7 f- P% J: e$ I
Publisher: Saunders; 6 edition (October 30, 2012)) \; R# t% `& P+ k; R) ]0 a6 h, R
Language: English/ N7 G( r  p$ z% o0 n
ISBN-10: 1455700908: a, l- ~. [( P0 Q* O3 V
Size: 52.3mb (original pdf)
7 @! s  Q/ T: V, ?- P5 K/ t) [3 w
8 W' ^/ Q. R4 ?0 R: [8 n6 N( x2013 BMA Medical Book Awards Highly Commended in Public Health!$ `! g0 T8 E* r, Y
Apply the latest vaccination knowledge with a reference that Bill Gates calls "an indispensable guide to the enhancement of the well-being of our world." Inside Vaccines, you’ll find comprehensive and current coverage of every aspect of vaccination, from the development of each vaccine to its use in reducing disease. This medical reference book offers the expert information you need to apply the very latest techniques and information in your practice!7 _- }0 ?/ C0 H5 M; q1 D/ Z

! Y# A- Z$ c5 ^4 x- SGain a complete understanding of each disease, including clinical characteristics, microbiology, pathogenesis, diagnosis, and treatment, as well as epidemiology and public health and regulatory issues.
# l5 g# }8 |/ x: _- g: B; CUpdate your knowledge of both existing vaccines and vaccines currently in the research and development stage.
0 M3 K9 @. G6 h: `4 kGet complete answers on each vaccine, including its stability, immunogenicity, efficacy, duration of immunity, adverse events, indications, contraindications, precautions, administration with other vaccines, and disease-control strategies.: v" N* I$ V7 [/ \" c% s' f
Analyze the cost-benefit and cost-effectiveness of different vaccine options.
% P8 w! t6 C6 R3 k5 @$ JClearly visualize concepts and objective data through an abundance of tables and figures.' e: Y# ]: e1 n% [9 i
Perform seamless searches of the complete text online, access all the references, and download all the images at www.expertconsult.com.
  P1 |* O0 b5 XMake optimal use of the latest vaccines for pneumococcal disease, rotavirus, human papillomavirus, herpes zoster, meningococcal disease, and much more.
1 n* \6 D3 B0 P' x8 yStay at the forefront of new developments with completely updated chapters on malaria and HIV vaccines, a new chapter on vaccine regulations across the world, and many other revisions throughout.  U! Y3 x# p" S( B3 b
& S3 m/ T- @7 r, s
Download link: http://pan.baidu.com/s/1i5NxwLR
' s1 R; ]. F. m) J. \3 ^2 G" rCode for downloading: dv96
2 F" [8 J+ X& f' A7 i
您需要登录后才可以回帖 登录 | 立即注册

本版积分规则

QQ|论坛App下载|Archiver|小黑屋|中国病毒学论坛    

GMT+8, 2024-11-26 07:33 , Processed in 0.205800 second(s), 28 queries .

Powered by Discuz! X3.2

© 2001-2013 Comsenz Inc.

快速回复 返回顶部 返回列表